Stellar stock soars after shareholders OK deal with Edesa
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Fate of Stellar Biotechnologies’ keyhole limpets up in the air
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Stellar reports higher revenues but net losses remain steady
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Stellar Biotechnologies expanding at Port of Hueneme
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
9 tri-county companies among Deloitte 2017 Technology Fast 500
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Stellar Biotechnologies reports $1.1 million loss for quarter
Stellar Biotechnologies, based in Port Hueneme, reported drops in both revenues and expenses for the quarter ended March 31. Revenues decreased 81 percent from $330,000 during the same quarter the previous year to $60,000 for the most recent quarter. The immunotherapy developer and manufacturer attributed the decrease to lower sales volume for pre-clinical studies, compared Read More →
Stellar Biotechnologies revenues up but losses grow
Stellar Biotechnologies’ revenues increased slightly during the third quarter of 2016 but losses widened as the company signed a new partnership with a French company and held an offering for institutional investors, the company said in a quarterly earnings report Aug. 8. Stellar revenues increased slightly from $157,748 during the third quarter of 2015 to Read More →
